Akero Therapeutics, Inc.
NASDAQ:AKRO
44.15 (USD) • At close March 14, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||
| Current Assets: | ||||||||
| Cash & Cash Equivalents
| 340.238 | 234.207 | 249.773 | 150.483 | 187.242 | 136.4 | 75.975 | 0.598 |
| Short Term Investments
| 402.84 | 315.803 | 101.676 | 37.775 | 81.145 | 71.612 | 0 | 0 |
| Cash and Short Term Investments
| 743.078 | 550.01 | 351.449 | 188.258 | 268.387 | 136.4 | 75.975 | 0.598 |
| Net Receivables
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets
| 27.302 | 9.952 | 7.448 | 10.648 | 5.916 | 3.298 | 2.312 | 0.08 |
| Total Current Assets
| 770.38 | 559.962 | 355.173 | 193.582 | 271.345 | 138.049 | 77.131 | 0.638 |
| Non-Current Assets: | ||||||||
| Property, Plant & Equipment, Net
| 0.755 | 1.026 | 1.289 | 1.549 | 1.793 | 0 | 0 | 0 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments
| 0 | 19.283 | 0 | 0 | 0.04 | 0.04 | 0.02 | 0.02 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 54.751 | 0 | 0.108 | 0.417 | 0.161 | 0.029 | 0 | 0 |
| Total Non-Current Assets
| 55.506 | 20.309 | 1.397 | 1.966 | 1.994 | 0.069 | 0.02 | 0.02 |
| Total Assets
| 825.886 | 580.271 | 356.57 | 195.548 | 273.339 | 138.118 | 77.151 | 0.658 |
| Liabilities & Equity: | ||||||||
| Current Liabilities: | ||||||||
| Account Payables
| 9.027 | 7.038 | 7.968 | 6.706 | 3.428 | 0.947 | 1.373 | 0.06 |
| Short Term Debt
| 0.631 | 0.522 | 0.325 | 0.205 | 0.294 | 0.085 | 0 | 0 |
| Tax Payables
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities
| 30.096 | 11.568 | 10.79 | 18.217 | 9.389 | 8.337 | 0.969 | 0.162 |
| Total Current Liabilities
| 39.754 | 19.128 | 19.083 | 25.128 | 13.111 | 9.369 | 2.342 | 0.222 |
| Non-Current Liabilities: | ||||||||
| Long Term Debt
| 1.058 | 25.783 | 10.62 | 2.622 | 3.032 | 0 | 0 | 0 |
| Deferred Revenue Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 34.962 | 0.054 | 0.305 | -1.311 | -1.516 | 0.023 | 124.728 | 5 |
| Total Non-Current Liabilities
| 36.02 | 25.837 | 10.925 | 1.311 | 1.516 | 0.023 | 124.728 | 5 |
| Total Liabilities
| 75.774 | 44.965 | 30.008 | 26.439 | 14.627 | 9.392 | 127.07 | 5.222 |
| Equity: | ||||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 0 | 138.118 | 124.728 | 5 |
| Common Stock
| 0.007 | 0.006 | 0.005 | 0.004 | 0.004 | 0.003 | 0 | 0 |
| Retained Earnings
| -826.156 | -574.096 | -422.337 | -310.304 | -209.527 | -130.32 | -86.565 | -4.564 |
| Accumulated Other Comprehensive Income/Loss
| 0.948 | 0.27 | 0.037 | -0.027 | -0.003 | -0.006 | 0 | 0 |
| Other Total Stockholders Equity
| 1,575.313 | 1,109.126 | 748.857 | 479.436 | 468.238 | 259.049 | -88.082 | -5 |
| Total Shareholders Equity
| 750.112 | 535.306 | 326.562 | 169.109 | 258.712 | 128.726 | -49.919 | -4.564 |
| Total Equity
| 750.112 | 535.306 | 326.562 | 169.109 | 258.712 | 128.726 | -49.919 | -4.564 |
| Total Liabilities & Shareholders Equity
| 825.886 | 580.271 | 356.57 | 195.548 | 273.339 | 138.118 | 77.151 | 0.658 |